* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jagsonpal Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jagsonpal Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jagsonpal Pharmaceuticals (BOM:507789) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jagsonpal Pharmaceuticals and its competitors. According to the industry distribution chart, Jagsonpal Pharmaceuticals ranks #159 out of 956 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Jagsonpal Pharmaceuticals' FCF Margin % too high?
Jagsonpal Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, Jagsonpal Pharmaceuticals ranks #159 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jagsonpal Pharmaceuticals ranks #159 out of 956 companies for FCF Margin %. This places Jagsonpal Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jagsonpal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jagsonpal Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (BOM:507789) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹204.87, compared to a current price of ₹231.25 — trading 12.9% above its estimated fair value. The current FCF Margin % is 0.00%. Jagsonpal Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (BOM:507789), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jagsonpal Pharmaceuticals (BOM:507789) Overvalued in 2026?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹231.25 is trading 12.9% above its estimated GF Value™ of ₹204.87.
GuruFocus considers Jagsonpal Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for BOM:507789:
FCF Margin %: 0.00%
GF Value™: ₹204.87 vs. price of ₹231.25 (12.9% above fair value)
No single metric tells the full story. See the BOM:507789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
67GF Score
Get the complete analysis for BOM:507789
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507789 has been successfully added to your 
